Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.37 |
| ▸ | PPARG | P37231 | 8/20 | 0.37 |
| ▸ | PPARA | Q07869 | 8/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490798 | 1.00 | AAK1 (0.42) | AAK1CACNA1BPPARGPPARAPPARD | |
| SCHEMBL490473 | 1.00 | AAK1 (0.42) | AAK1CACNA1BPPARGPPARAPPARD | |
| SCHEMBL1147482 | 0.90 | AAK1 (0.37) | AAK1CACNA1BPPARGPPARAPPARD | |
| SCHEMBL490824 | 0.89 | AAK1 (0.40) | AAK1CACNA1BPPARGPPARAPPARD | |
| SCHEMBL1147713 | 0.88 | AAK1 (0.35) | AAK1CACNA1BPPARGPPARAPPARD | |
| SCHEMBL1147406 | 0.88 | PRMT5 (0.39) | AAK1CACNA1BPPARGPPARAPRMT5 | |
| SCHEMBL490476 | 0.87 | PPARG (0.37) | AAK1CACNA1BPPARGPPARAPPARD | |
| SCHEMBL491162 | 0.84 | CACNA1B (0.51) | AAK1CACNA1BPPARGPPARAPPARD | |
| SCHEMBL490918 | 0.84 | CACNA1B (0.51) | AAK1CACNA1BPPARGPPARAPPARD | |
| SCHEMBL3810376 | 0.78 | AAK1 (0.47) | AAK1PPARGPPARAPPARDPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106091-B2 | Inhibitors of IKK-beta serine-threonine protein kinase | CHROMA THERAPEUTICS LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| EP-2086956-B1 | INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD (GB) | 2011-09-14 | — | — | EP | disclosed |
| US-20100069473-A1 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069473-A1 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase | IKBKB, IKBKE, CHUK | AAK1 1469/4885CACNA1B 2344/4885PPARG 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.